Hepatoblastoma

Back to Top
Last updated on 2024-07-23:10 regimens on this page
10 variants on this page
=High-risk, upfront therapy=
==COG AHEP0731 protocol H - responders==
===Regimen===
====Chemotherapy, VIT portion (cycles 1 & 2)====
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
*Irinotecan (Camptosar) by the following weight-based criteria:
**Less than 10 kg: 1.67 mg/kg (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
**10 kg or more: 50 mg/m2 (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
====Targeted therapy, VIT portion (cycles 1 & 2)====
*Temsirolimus (Torisel) by the following weight-based criteria:
**Less than 10 kg: 1.2 mg/kg IV over 30 minutes once per day on days 1 & 8
**10 kg or more: 35 mg/m2 IV over 30 minutes once per day on days 1 & 8
====Chemotherapy, C5VD portion (cycles 3 to 6)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Chemotherapy, VIT portion (cycle 7)====
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
*Irinotecan (Camptosar) by the following weight-based criteria:
**Less than 10 kg: 1.67 mg/kg (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
**10 kg or more: 50 mg/m2 (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
====Targeted therapy, VIT portion (cycle 7)====
*Temsirolimus (Torisel) by the following weight-based criteria:
**Less than 10 kg: 1.2 mg/kg IV over 30 minutes once per day on days 1 & 8
**10 kg or more: 35 mg/m2 IV over 30 minutes once per day on days 1 & 8
====Chemotherapy, C5VD portion (cycles 8 & 9)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Supportive therapy, C5VD portion (cycles 8 & 9)====
*Dexrazoxane (Zinecard) by the following weight-based criteria:
**Less than 10 kg: 10 mg/kg IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
**10 kg or more: 300 mg/m2 IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
====Chemotherapy, VIT portion (cycle 10)====
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
*Irinotecan (Camptosar) by the following weight-based criteria:
**Less than 10 kg: 1.67 mg/kg (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
**10 kg or more: 50 mg/m2 (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
====Targeted therapy, VIT portion (cycle 10)====
*Temsirolimus (Torisel) by the following weight-based criteria:
**Less than 10 kg: 1.2 mg/kg IV over 30 minutes once per day on days 1 & 8
**10 kg or more: 35 mg/m2 IV over 30 minutes once per day on days 1 & 8
21-day cycle for 10 cycles
===References===
#None yet identified
==COG AHEP0731 protocol H - non-responders==
===Regimen===
====Chemotherapy, VIT portion (cycles 1 & 2)====
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 1 & 8
*Irinotecan (Camptosar) by the following weight-based criteria:
**Less than 10 kg: 1.67 mg/kg (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
**10 kg or more: 50 mg/m2 (maximum dose of 100 mg) IV over 90 minutes once per day on days 1 to 5
====Targeted therapy, VIT portion (cycles 1 & 2)====
*Temsirolimus (Torisel) by the following weight-based criteria:
**Less than 10 kg: 1.2 mg/kg IV over 30 minutes once per day on days 1 & 8
**10 kg or more: 35 mg/m2 IV over 30 minutes once per day on days 1 & 8
====Chemotherapy, C5VD portion (cycles 3 to 6)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Chemotherapy, C5VD portion (cycles 7 to 8)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Supportive therapy, C5VD portion (cycles 7 to 8)====
*Dexrazoxane (Zinecard) by the following weight-based criteria:
**Less than 10 kg: 10 mg/kg IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
**10 kg or more: 300 mg/m2 IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
21-day cycle for 8 cycles
===References===
#None yet identified
==COG AHEP0731 protocol W==
===Regimen===
Study 	Dates of enrollment	Evidence
Katzenstein et al. 2017 (COG AHEP0731 HR)	2009-09 to 2012-02 	Non-randomized
====Chemotherapy====
*Irinotecan (Camptosar) by the following weight-based criteria:
**Less than 10 kg: 1.67 mg/kg IV over 90 minutes once per day on days 1 to 5
**10 kg or more: 50 mg/m2 IV over 90 minutes once per day on days 1 to 5
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg IV once per day on days 1 & 8
**10 kg or more: 1.5 mg/m2 IV once per day on days 1 & 8
21-day cycle for 2 cycles
====Subsequent treatment====
*Depends on response; see paper for details
===References===
#COG AHEP0731 HR: Katzenstein HM, Furman WL, Malogolowkin MH, Krailo MD, McCarville MB, Towbin AJ, Tiao GM, Finegold MJ, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Rodriguez-Galindo C, Meyers RL. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer. 2017 Jun 15;123(12):2360-2367. Epub 2017 Feb 17. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00980460
==SIOPEL-4 protocol, resectable after A3==
Study 	Dates of enrollment 	Evidence
Zsiros et al. 2013 (SIOPEL-4)	2005-01-01 to 2009-08-31	Non-randomized
===Neoadjuvant, "Cycles A1, A2, A3"===
====Chemotherapy====
*Cisplatin (Platinol) as follows:
**Cycle 1: 80 mg/m2 IV continuous infusion over 24 hours, started on day 1, then 70 mg/m2 IV continuous infusion over 24 hours, started on days 8 & 15 (total dose: 220 mg/m2)
**Cycle 2: 70 mg/m2 IV continuous infusion over 24 hours, started on days 1, 8, 15 (total dose: 210 mg/m2)
**Cycle 3: 70 mg/m2 IV continuous infusion over 24 hours, started on days 1 & 8 (total dose: 140 mg/m2)
*Doxorubicin (Adriamycin) as follows:
**Cycles 1 & 2: 30 mg/m2/day IV continuous infusion over 48 hours, started on day 8 (total dose per cycle: 60 mg/m2)
**Cycle 3: 30 mg/m2/day IV continuous infusion over 48 hours, started on day 1 (total dose: 60 mg/m2)
28-day cycle for 3 cycles, followed by determination of resectability, then:
===Definitive===
====Local therapy====
*Surgical resection, including liver transplantation and metastasectomy, if needed
===Adjuvant, "Cycle C"===
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6.6 IV over 60 minutes once on day 1
*Doxorubicin (Adriamycin) 20 mg/m2/day IV continuous infusion over 48 hours, started on day 1 (total dose per cycle: 40 mg/m2)
21-day cycle for 3 cycles
===References===
#SIOPEL-4: Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug;14(9):834-42. Epub 2013 Jul 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00077389
==SIOPEL-4 protocol, unresectable after A3==
Study 	Dates of enrollment 	Evidence
Zsiros et al. 2013 (SIOPEL-4)	2005-01-01 to 2009-08-31	Non-randomized
===Neoadjuvant, "Cycles A1, A2, A3"===
====Chemotherapy====
*Cisplatin (Platinol) as follows:
**Cycle 1: 80 mg/m2 IV continuous infusion over 24 hours, started on day 1, then 70 mg/m2 IV continuous infusion over 24 hours, started on days 8 & 15 (total dose: 220 mg/m2)
**Cycle 2: 70 mg/m2 IV continuous infusion over 24 hours, started on days 1, 8, 15 (total dose: 210 mg/m2)
**Cycle 3: 70 mg/m2 IV continuous infusion over 24 hours, started on days 1 & 8 (total dose: 140 mg/m2)
*Doxorubicin (Adriamycin) as follows:
**Cycles 1 & 2: 30 mg/m2/day IV continuous infusion over 48 hours, started on day 8 (total dose per cycle: 60 mg/m2)
**Cycle 3: 30 mg/m2/day IV continuous infusion over 48 hours, started on day 1 (total dose: 60 mg/m2)
28-day cycle for 3 cycles, followed by determination of unresectability, then:
===Neoadjuvant, "Cycle B"===
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 10.6 IV over 60 minutes once on day 1
*Doxorubicin (Adriamycin) 25 mg/m2/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 75 mg/m2)
21-day cycle for 2 cycles, followed by:
===Definitive===
====Local therapy====
*Surgical resection, including liver transplantation and metastasectomy, if needed
===References===
#SIOPEL-4: Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug;14(9):834-42. Epub 2013 Jul 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00077389
=Intermediate-risk, upfront therapy=
==COG AHEP0731 protocol F==
===Regimen===
====Chemotherapy, C5VD portion (cycles 1 to 4)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Chemotherapy, C5VD portion (cycles 5 & 6)====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
*Doxorubicin (Adriamycin) by the following weight-based criteria:
**Less than 10 kg: 1 mg/kg IV over 15 minutes once per day on days 1 & 2
**10 kg or more: 30 mg/m2 IV over 15 minutes once per day on days 1 & 2
====Supportive therapy, C5VD portion (cycles 5 & 6)====
*Dexrazoxane (Zinecard) by the following weight-based criteria:
**Less than 10 kg: 10 mg/kg IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
**10 kg or more: 300 mg/m2 IV over 5 to 15 minutes immediately prior to doxorubicin on days 1 & 2
21-day cycle for 6 cycles
===References===
#Not yet identified
=Low-risk, upfront therapy=
==COG AHEP0731 protocol T==
===Regimen===
====Preceding treatment====
*Surgical resection
====Chemotherapy====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV once over 6 hours on day 1
*Fluorouracil (5-FU) by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV push over 2 to 4 minutes once on day 2
**10 kg or more: 600 mg/m2 IV push over 2 to 4 minutes once on day 2
*Vincristine (Oncovin) by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV push or infusion once per day on days 2, 9, 16
21-day cycle for 2 cycles
===References===
#COG AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article link to PMC article EuroPMC NCT00980460
=Neoadjuvant therapy=
==Cisplatin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Perilongo et al. 2009 (SIOPEL 3)	1998-2006 	Phase 3 (E-de-esc)	Cisplatin & Doxorubicin 	Non-inferior complete resection rate (primary endpoint)	
Brock et al. 2018 (SIOPEL 6) 	2007-2014 	Phase 3 (C) 	Cisplatin & Sodium thiosulfate	 	More hearing loss
====Chemotherapy====
*Cisplatin (Platinol) 80 mg/m2 IV continuous infusion over 24 hours, started on day 1
14-day cycle for 4 cycles
===References===
# SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003912
# SIOPEL 6: Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. link to original article link to PMC article EuroPMC NCT00652132
=Adjuvant therapy=
==Cisplatin & Fluorouracil (CF) & Vincristine==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Katzenstein et al. 2019 (COG AHEP0731)	2010-2014 	Phase 3 (E-esc)	Observation	Seems to have longer EFS (primary endpoint)
For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.
====Preceding treatment====
*Curative surgical resection
====Chemotherapy====
*Cisplatin (Platinol) by the following weight-based criteria:
**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
**10 kg or more: 100 mg/m2 IV over 6 hours once on day 1
*Fluorouracil by the following weight-based criteria:
**Less than 10 kg: 20 mg/kg IV once on day 2
**10 kg or more: 600 mg/m2 IV once on day 2
*Vincristine by the following weight-based criteria:
**Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
**10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 2, 9, 16
21-day course; to be given within 42 days of resection
===References===
#COG AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article link to PMC article EuroPMC NCT00980460
=All lines of therapy=
==Cisplatin & Doxorubicin==
PLADO: PLAtinol (Cisplatin) & DOxorubicin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Ortega et al. 2000 	1989-1992 	Phase 3 (E-switch-ic)	CF & Vincristine	 	More toxic (primary endpoint)
Pritchard et al. 2000 (SIOPEL 1)	1990-1994 	Non-randomized 	 	 	
Perilongo et al. 2009 (SIOPEL 3)	1998-2006 	Phase 3 (C) 	Cisplatin 	Non-inferior complete resection rate	
Note: Cycle length was not specified.
====Chemotherapy====
*Cisplatin (Platinol) by the following age-based criteria:
**Younger than 1 year old: 3 mg/kg IV over 6 hours once on day 1, given first
**1 year old or older: 90 mg/m2 IV over 6 hours once on day 1, given first
*Doxorubicin (Adriamycin) 20 mg/m2/day IV continuous infusion over 96 hours, started on day 1, given second (total dose per cycle: 80 mg/m2)
4 cycles
===References===
# Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# SIOPEL 1: Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. link to original article EuroPMC 
# SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article EuroPMC NCT00003912
Category:Hepatoblastoma regimens
Category:Disease-specific pages
Category:Pediatric solid tumors